ATHOS KG, Holzkirchen, Germany is the sole shareholder of AT Impf GmbH, Munich, Germany and beneficial

owner of our ordinary shares. ATHOS KG via AT Impf GmbH has de facto control over BioNTech based on its

substantial shareholding, which practically enables it to exercise the majority of voting rights to pass resolutions

Our key management personnel have been defined as the members of the Management Board and the



	Years ended December 31,

(in millions €)	2024	2023	2022
Management Board(1)	13.0	8.3	15.0
Fixed compensation	4.0	3.9	2.9
Fringe benefits	0.2	—	—
Short-term incentive – first installment	0.8	0.7	0.6
Short-term incentive – second installment(2)	0.6	1.0	0.7
Other variable compensation(3)	1.3	0.8	0.1
Share-based payments (incl. long-term incentive)(4)	6.1	1.9	10.7
Supervisory Board	0.9	0.6	0.5
Total compensation of key management personnel	13.9	8.9	15.5

(1)During the year ended December 31, 2024, Sean Marett retired from the Management Board with effect as of July 1,

2024. Therefore, his compensation until his departure date is presented on a pro-rata basis in this table. The following

compensation pursuant to his separation agreement subsequent to his departure date and thus as former Management

Board member are not included in this table: a severance payment of €275,000, an additional payment of €39,000 in

respect of the 2024 STI, a grant of 5,760 phantom options in respect of the 2024 LTI and a payment of €477,030 in

(2)The fair value of the second installment of the short-term incentive compensation which has been classified as a cash-

settled share-based payment arrangement was determined pursuant to the regulations of IFRS 2 “Share-based

Payments”. This table shows the pro-rata share of personnel expenses for the respective financial year, which are

recognized over the award’s vesting period beginning as of the service commencement date (date when entering or

renewing service agreements) until each separate determination date and are remeasured until settlement date.

(3)Represents for the financial year 2024 the cash payment related to the one-time signing bonus granted to Annemarie

Hanekamp as part of her appointment to the Management Board, designed to compensate her for lower bonus payments

that she would receive as part of her compensation package with BioNTech and to recognize and appreciate her move to

BioNTech. For 2023, the amount represents the one-time signing cash payment related to James Ryan’s appointment to

the Management Board to provided compensation in lieu of participation in the LTI 2023 program and the one-time

special cash payment related to Jens Holstein to honor his contribution to BioNTech’s extraordinary financial

performance. For 2022, the amount includes a one-time signing and retention cash payment agreed when renewing the

(4)The fair value of the share-based payments was determined pursuant to the regulations of IFRS 2 “Stock-based

Payments”. This table shows the pro-rata share of personnel expenses resulting from stock-based compensation for the

respective financial year. During the years ended December 31, 2024, 2023 and 2022, the amounts included expenses

derived from a one-time signing bonus granted to Jens Holstein as of his appointment to the Management Board in the

form of 4,246 phantom shares as well as expenses derived from the one-time signing bonus granted to Annemarie

Hanekamp as of her appointment to the Management Board in the form of shares in the amount of €500,000.

The amounts disclosed in the table are the amounts recognized as an expense during the period.

Management Board members participated in our ESOP program (see Note 16). Out of the 5,152,410 option

rights granted to our Management Board under the ESOP 2018 program, 4,921,630 options were exercised

during the year ended December 31, 2022. The remaining 230,780 option rights were exercised by Sean Marett

in May 2023. During the year ended December 31, 2024, our CEO Prof. Ugur Sahin, M.D., exercised all

participated in the LTI 2020 Board Program, exercised 209,128 options in August 2024 while 38,968 options are

outstanding as of December 31, 2024 (see Note 16). For further information regarding outstanding options for

The total amount of transactions with ATHOS KG or entities controlled by it was as follows for the periods



	Years ended December 31,

(in millions €)	2024	2023	2022
Purchases of various goods and services from entities controlled by ATHOS KG	0.2	0.3	0.3
Purchases of property and other assets from entities controlled by ATHOS KG	—	—	62.5
Total	0.2	0.3	62.8

The amounts disclosed in the table are the amounts recognized as an expense during the period.

On December 22, 2022, we entered into a purchase agreement with Santo Service GmbH, pursuant to which we

acquired the real estate property An der Goldgrube 12 and the existing laboratory and office building including

any movable assets for a total consideration of €62.5 million. The purchase price was paid during the year ended

December 31, 2022. Santo Service GmbH is wholly owned by AT Impf GmbH, that is controlled by ATHOS KG.

The outstanding balances of transactions with ATHOS KG or entities controlled by them were as follows as of the

None of the balances are secured and no bad debt expense has been recognized in respect of amounts owed

A number of individuals in key positions can control or exercise significant influence over BioNTech SE. There

were no business relationships with individuals in key positions during the year ended December 31, 2024.